<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04857138</url>
  </required_header>
  <id_info>
    <org_study_id>WP42627</org_study_id>
    <secondary_id>2020-004489-21</secondary_id>
    <nct_id>NCT04857138</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors</brief_title>
  <official_title>An Open-Label, Multicenter, Dose-Escalation and Expansion, Phase I Study to Evaluate Safety, Pharmacokinetics, And Anti-Tumor Activity of RO7300490, A Fibroblast Activation Protein-Î± (FAP) Targeted CD40 Agonist, as Single Agent or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the safety, pharmacokinetics and anti-tumor activity of RO7300490 as a&#xD;
      single agent or in combination with atezolizumab. The study will consist of 3 parts: [Part 1]&#xD;
      Dose-Escalation of RO7300490 as a single agent; [Part 2] Dose-Escalation of RO7300490 in&#xD;
      combination with atezolizumab and [Part 3] Dose-Expansion of RO7300490 in combination with&#xD;
      atezolizumab in selected cancer types.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2021</start_date>
  <completion_date type="Anticipated">August 17, 2026</completion_date>
  <primary_completion_date type="Anticipated">August 17, 2026</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs) (Parts 1 and 2)</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Dose-Limiting Toxicities (DLTs) (Parts 1 and 2)</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) (Part 3)</measure>
    <time_frame>Up to 48 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under The Curve (AUC) of RO7300490 (Parts 1, 2 and 3)</measure>
    <time_frame>Up to 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Concentration (Cmin) of RO7300490 (Parts 1, 2 and 3)</measure>
    <time_frame>Up to 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) of RO7300490 (Parts 1, 2 and 3)</measure>
    <time_frame>Up to 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of RO7300490 (Parts 1, 2 and 3)</measure>
    <time_frame>Up to 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss) of RO7300490 (Parts 1, 2 and 3)</measure>
    <time_frame>Up to 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Anti-RO7300490 Antibodies (Parts 1, 2 and 3)</measure>
    <time_frame>Up to 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) (Parts 1 and 2)</measure>
    <time_frame>Up to 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) (Parts 1, 2 and 3)</measure>
    <time_frame>Up to 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) (Parts 1, 2 and 3)</measure>
    <time_frame>Up to 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) On-Treatment (Parts 1, 2 and 3)</measure>
    <time_frame>Up to 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs) (Part 3)</measure>
    <time_frame>Up to 48 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Part 1: Dose Escalation (RO7300490 Monotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive escalating doses of RO7300490 intravenously (IV) as a single agent for up to 24 months maximum or until progressive disease, unacceptable toxicities, death, or withdrawal of consent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Dose Escalation (RO7300490/atezolizumab combination therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive escalating doses of RO7300490 in combination with a fixed dose of atezolizumab IV (as per label) for up to 24 months maximum or until progressive disease, unacceptable toxicities, death, or withdrawal of consent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: Dose Expansion (Disease-specific Expansion(s))</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with selected types of advanced and/or metastatic tumors will receive the maximum tolerated dose (MTD) or recommended dose for expansion (RDE) (determined from Parts 1 and 2) of RO7300490 in combination with a fixed dose of atezolizumab IV (as per label). Treatment will be administered for up to 24 months maximum or until progressive disease, unacceptable toxicities, death, or withdrawal of consent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7300490</intervention_name>
    <description>Participants will receive RO7300490, as described in the Arm Descriptions.</description>
    <arm_group_label>Part 1: Dose Escalation (RO7300490 Monotherapy)</arm_group_label>
    <arm_group_label>Part 2: Dose Escalation (RO7300490/atezolizumab combination therapy)</arm_group_label>
    <arm_group_label>Part 3: Dose Expansion (Disease-specific Expansion(s))</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Participants will receive Atezolizumab, as described in the Arm Descriptions.</description>
    <arm_group_label>Part 2: Dose Escalation (RO7300490/atezolizumab combination therapy)</arm_group_label>
    <arm_group_label>Part 3: Dose Expansion (Disease-specific Expansion(s))</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Life expectancy of &gt;= 12 weeks.&#xD;
&#xD;
          -  Histologically confirmed diagnosis of locally advanced and/or metastatic solid tumors&#xD;
             that are not amenable to standard therapy.&#xD;
&#xD;
          -  Radiologically measurable disease as defined by Response Evaluation Criteria in Solid&#xD;
             Tumors (RECIST) v1.1.&#xD;
&#xD;
          -  Agreement to provide protocol-specific biopsy material.&#xD;
&#xD;
          -  Adverse Events (AEs) from prior anti-cancer therapy resolved to Grade =&lt;1.&#xD;
&#xD;
          -  Adequate performance status and cardiovascular, hematological, liver, renal and&#xD;
             coagulation function.&#xD;
&#xD;
          -  For female participants of childbearing potential: agreement to remain abstinent&#xD;
             (refrain from heterosexual intercourse), use contraceptive measures and refrain from&#xD;
             donating eggs.&#xD;
&#xD;
          -  For male participants: agreement to remain abstinent (refrain from heterosexual&#xD;
             intercourse), use contraceptive measures and refrain from donating sperm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known central nervous system (CNS) primary tumors or metastases, including&#xD;
             leptomeningeal metastases.&#xD;
&#xD;
          -  Active second malignancy requiring anticancer treatment and/or palliative supportive&#xD;
             care.&#xD;
&#xD;
          -  Significant cardiovascular/cerebrovascular disease within 6 months prior to study&#xD;
             treatment start.&#xD;
&#xD;
          -  Any other diseases, metabolic dysfunction, physical examination finding or clinical&#xD;
             laboratory finding that gives reasonable suspicion of a disease or condition that&#xD;
             would contraindicate the use of an investigational drug.&#xD;
&#xD;
          -  Prior allogeneic bone marrow transplantation or prior solid organ transplantation.&#xD;
&#xD;
          -  Active or history of autoimmune disease.&#xD;
&#xD;
          -  Known hypersensitivity to any of the components of RO7300490 formulation or to&#xD;
             components of atezolizumab formulation.&#xD;
&#xD;
          -  Pregnancy, lactation or breastfeeding.&#xD;
&#xD;
          -  Dementia or altered mental status that would prohibit informed consent.&#xD;
&#xD;
          -  Major surgery or significant traumatic injury within 28 days prior to the first study&#xD;
             drug administration (excluding biopsies) or anticipation of the need for major surgery&#xD;
             during study treatment.&#xD;
&#xD;
          -  Treatment with radiotherapy, chemotherapy, hormonal therapy, targeted therapy,&#xD;
             immunotherapy or investigational drug concurrent or within 28 days or 5 half-lives of&#xD;
             the drug (whichever is shorter) before the first study drug administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: WP42627 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rigshospitalet; Fase 1 Enhed - Onkologi</name>
      <address>
        <city>KÃ¸benhavn Ã</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra; Servicio de Oncologia</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Univ Vall d'Hebron; Servicio de Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra Madrid; Servicio de OncologÃ­a</name>
      <address>
        <city>Madrid</city>
        <zip>28027</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>START Madrid-FJD, Hospital Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Western General Hospital; Edinburgh Cancer Center</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guys and St Thomas Hospital; OHCT Clinical Trials</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Christie Hospital NHS Trust; Experimental Cancer Medicine Team</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

